(2-068) Cost Efficiency of Trilaciclib, A First-in-Class Kinase Inhibitor Providing Multilineage Myeloprotection, and Expanded Budget-Neutral Access to Multilineage Myeloprotection for Extensive-Stage Small Cell Lung Cancer Patients
Monday, December 4, 2023
10:45 AM – 11:45 AM
Location: Hall E, Lower Level
Co-Author(s): Gabrielle Murphy, Preston Ngo, Starley Pollei, Ivo Abraham
